Trevi Therapeutics (NASDAQ:TRVI) Given New $24.00 Price Target at JonesTrading

Trevi Therapeutics (NASDAQ:TRVI) had its target price dropped by equities research analysts at JonesTrading from $25.00 to $24.00 in a report released on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. JonesTrading’s price target points to a potential upside of 124.11% from the stock’s current price.

TRVI has been the subject of a number of other reports. Leerink Partners boosted their target price on Trevi Therapeutics from $13.00 to $16.00 and gave the company an “outperform” rating in a research note on Wednesday, November 19th. Needham & Company LLC lifted their price objective on Trevi Therapeutics from $22.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday. Morgan Stanley decreased their price objective on Trevi Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a research report on Wednesday. D. Boral Capital reissued a “buy” rating and set a $19.00 target price on shares of Trevi Therapeutics in a research note on Wednesday. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Trevi Therapeutics in a research note on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Trevi Therapeutics has a consensus rating of “Buy” and an average target price of $21.60.

Trevi Therapeutics Price Performance

Shares of NASDAQ TRVI traded up $0.02 during midday trading on Thursday, reaching $10.71. 808,062 shares of the stock were exchanged, compared to its average volume of 1,376,696. Trevi Therapeutics has a 12 month low of $4.85 and a 12 month high of $14.39. The company has a market capitalization of $1.37 billion, a price-to-earnings ratio of -33.47 and a beta of 0.94. The business has a 50-day simple moving average of $11.15 and a two-hundred day simple moving average of $10.93.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings data on Tuesday, March 17th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.04. Equities research analysts expect that Trevi Therapeutics will post -0.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of TRVI. Russell Investments Group Ltd. lifted its stake in Trevi Therapeutics by 194.5% in the second quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock valued at $25,000 after acquiring an additional 2,996 shares during the last quarter. Hilton Head Capital Partners LLC acquired a new stake in Trevi Therapeutics in the 4th quarter valued at about $40,000. Caitong International Asset Management Co. Ltd bought a new position in Trevi Therapeutics during the fourth quarter worth about $50,000. Strs Ohio bought a new position in Trevi Therapeutics during the first quarter worth about $52,000. Finally, Catalyst Funds Management Pty Ltd acquired a new position in Trevi Therapeutics during the second quarter worth approximately $56,000. 95.76% of the stock is owned by institutional investors and hedge funds.

Trevi Therapeutics News Roundup

Here are the key news stories impacting Trevi Therapeutics this week:

• Positive Sentiment: FDA alignment: Trevi received End-of-Phase-2 alignment from the FDA and plans two pivotal Phase 3 trials for idiopathic pulmonary fibrosis (IPF)-related chronic cough — a major de‑risking step that supports future value if trials succeed. Trevi Therapeutics plans two pivotal phase III trials for IPF-related chronic cough as FDA
• Positive Sentiment: Q4 beat and business update: Trevi reported EPS of ($0.06) vs. consensus ~($0.10) for Q4 2025 and reiterated the Phase 3 program and other strategic updates on the earnings call and press release — an earnings beat that reduces near-term execution risk. Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results
• Positive Sentiment: Analyst bullish moves: Needham raised its price target from $22 to $24 (buy), signaling improved long‑term upside expectations tied to the Phase 3 program. Needham price target raise
• Positive Sentiment: HC Wainwright maintains Buy and modeled multi‑quarter EPS path: HC Wainwright reiterated a Buy and published quarterly EPS forecasts for 2026–2026 while projecting FY2030 upside — analyst modeling that supports higher targets if clinical progress continues. HC Wainwright estimates (MarketBeat)
• Positive Sentiment: D. Boral Capital reaffirmed buy with a $19 target, another vote of confidence from the sellside. D. Boral Capital reaffirmation
• Neutral Sentiment: Morgan Stanley adjustment: Morgan Stanley trimmed its price target from $19 to $18 but kept an “overweight” rating — a modest calibration that still implies upside but tempers some enthusiasm. Morgan Stanley target adjustment
• Neutral Sentiment: Recent coverage & valuation pieces are running alongside the clinical news — analysts and outlets are recalculating valuation given Phase 3 alignment, which can amplify intraday swings as investors reassess probabilities. Valuation after FDA green light (Yahoo)
• Negative Sentiment: Market reaction & liquidity: Despite the favorable clinical and earnings news, shares are trading marginally lower on lighter-than-average intraday volume and mixed analyst signals — suggesting near‑term profit‑taking and that some investors are waiting for clearer Phase 3 design/ timelines before committing. MarketBeat intraday/volume summary

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.